Arondite | $12,000,000 | (May 2, 2025)
SafeHeal | $39,548,022 | (May 2, 2025)
Ceto | $4,800,000 | (May 2, 2025)
Certified by Founder
Lodge
Bryleos
start up
United States
- Johnson City, Tennessee
- 14/06/2023
- Seed
- $5,000,000
Early clinical stage therapeutics company developing BNAD101, a patent-pending oral composition of NAD+ clinically proven to increase intracellular NAD+. BNAD101 is a potential high-value medicine to treat challenging and costly neurological disorders.
In 2022, the Company completed its double-blind, placebo-controlled proof of concept study at the Institute of Systems Biology. The study of 60 healthy adults demonstrated BNAD101 had a 52% increase in intracellular NAD levels against placebo within just 5 days, effectively validating the potential of BNAD101 in treating not only chronic neurological conditions but conditions were swift response is critical.
Bryleos: More Life While Living
- Industry Biotechnology Research
- Website https://bryleos.com/
- LinkedIn https://www.linkedin.com/company/bryleos/
Gruve | $20,000,000 | (May 2, 2025)
Peek(US) | $5,000,000 | (May 2, 2025)
ChiroHD | $26,000,000 | (May 2, 2025)
Paramark.com | $8,000,000 | (May 2, 2025)
Zoe Financial | $30,000,000 | (May 2, 2025)
Hoofprint Biome | $15,000,000 | (May 2, 2025)
Stately Bio | $12,000,000 | (May 2, 2025)
SatLeo Labs | $3,300,000 | (May 2, 2025)
QbDVision | $13,000,000 | (May 2, 2025)